Literature DB >> 1310899

Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase.

H Y Lin1, X F Wang, E Ng-Eaton, R A Weinberg, H F Lodish.   

Abstract

A cDNA encoding the TGF-beta type II receptor protein has been isolated by an expression cloning strategy. The cloned cDNA, when transfected into COS cells, leads to overexpression of an approximately 80 kd protein that specifically binds radioiodinated TGF-beta 1. Excess TGF-beta 1 competes for binding of radioiodinated TGF-beta 1 in a dose-dependent manner and is more effective than TGF-beta 2. The predicted receptor structure includes a cysteine-rich extracellular domain, a single hydrophobic transmembrane domain, and a predicted cytoplasmic serine/threonine kinase domain. A chimeric protein containing the intracellular domain of the type II receptor and expressed in E. coli can phosphorylate itself on serine and threonine residues in vitro, indicating that the cytoplasmic domain of the type II receptor is a functional kinase. This result implicates serine/threonine phosphorylation as an important mechanism of TGF-beta receptor-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310899     DOI: 10.1016/0092-8674(92)90152-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  184 in total

1.  An antibody present in normal human serum inhibits the binding of cytokines to their receptors in an in vitro system.

Authors:  D E Mosedale; D J Grainger
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  Sequential resonance assignments of the extracellular ligand binding domain of the human TGF-beta type II receptor.

Authors:  A P Hinck; K P Walker; N R Martin; S Deep; C S Hinck; D I Freedberg
Journal:  J Biomol NMR       Date:  2000-12       Impact factor: 2.835

3.  TGF-beta in mammary development and neoplasia.

Authors:  C L Arteaga; H L Moses
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-10       Impact factor: 2.673

4.  Relationship between grade of microsatellite instability and target genes of mismatch repair pathways in sporadic colorectal carcinoma.

Authors:  G Togo; Y Shiratori; M Okamoto; Y Yamaji; M Matsumura; T Sano; T Motojima; M Omata
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

Review 5.  Molecular signal integration. Interplay between serine, threonine, and tyrosine phosphorylation.

Authors:  J Posada; J A Cooper
Journal:  Mol Biol Cell       Date:  1992-06       Impact factor: 4.138

6.  Cloning and characterization of a human type II receptor for bone morphogenetic proteins.

Authors:  B L Rosenzweig; T Imamura; T Okadome; G N Cox; H Yamashita; P ten Dijke; C H Heldin; K Miyazono
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.

Authors:  L R Lund; V Ellis; E Rønne; C Pyke; K Danø
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

8.  Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.

Authors:  N Sanderson; V Factor; P Nagy; J Kopp; P Kondaiah; L Wakefield; A B Roberts; M B Sporn; S S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  Characterization of a human hepatoma cell line with acquired resistance to growth inhibition by transforming growth factor beta 1 (TGF-beta 1).

Authors:  K Hasegawa; Z Wang; M Inagaki; B I Carr
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-01       Impact factor: 2.416

10.  Different domains regulate homomeric and heteromeric complex formation among type I and type II transforming growth factor-beta receptors.

Authors:  Maya Mouler Rechtman; Alex Nakaryakov; Keren E Shapira; Marcelo Ehrlich; Yoav I Henis
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.